A PHASE II/III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, COGNITIVE ENDPOINT, MULTICENTER STUDY OF POTENTIAL DISEASE MODIFYING THERAPIES IN INDIVIDUALS AT RISK FOR AND WITH DOMINANTLY INHERITED ALZHEIMER’S DISEASE (“PROTOCOL”). THE “STUDY” FOR THE PURPOSE OF THIS AGREEMENT IS THAT PORTION OF THE PROTOCOL THAT IS DESCRIBED AS “COGNITIVE RUN-IN”